Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement

Vasileios Chortis, Angela E. Taylor, Petra Schneider, Jeremy W. Tomlinson, Beverly A. Hughes, Donna M. O'Neil, Rossella Libé, Bruno Allolio, Xavier Bertagna, Jérôme Bertherat, Felix Beuschlein, Martin Fassnacht, Niki Karavitaki, Massimo Mannelli, Franco Mantero, Giuseppe Opocher, Emilio Porfiri, Marcus Quinkler, Mark Sherlock, Massimo TerzoloPeter Nightingale, Cedric H L Shackleton, Paul M. Stewart, Stefanie Hahner, Wiebke Arlt

Research output: Contribution to journalArticlepeer-review

Abstract

Context: Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2- dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substance, but there is limited information on distinct effects on steroidogenesis. However, adrenal insufficiency and male hypogonadism are widely recognized side effects of mitotane treatment. Objective: Our objective was to define the impact of mitotane treatment on in vivo steroidogenesis in patients with ACC. Setting and Design: At seven European specialist referral centers for adrenal tumors, we analyzed 24-h urine samples (n = 127) collected from patients with ACC before and during mitotane therapy in the adjuvant setting (n = 23) or for metastatic ACC (n = 104). Urinary steroid metabolite excretion was profiled by gas chromatography/mass spectrometry in comparison with healthy controls (n = 88). Results: We found a sharp increase in the excretion of 6β-hydroxycortisol over cortisol (P <0.001), indicative of a strong induction of the major drug-metabolizing enzyme cytochrome P450 3A4. The contribution of 6β-hydroxycortisol to total glucocorticoid metabolites increased from 2%(median, interquartile range 1-4%) to 56% (39-71%) during mitotane treatment. Furthermore, we documented strong inhibition of systemic 5α-reductase activity, indicated by a significant decrease in 5α-reduced steroids, including 5α-tetrahydrocortisol, 5α-tetrahydrocorticosterone, and androsterone (all P <0.001). The degree of inhibition was similar to that in patients with inactivating 5α-reductase type 2 mutations (n = 23) and patients receiving finasteride (n = 5), but cluster analysis of steroid data revealed a pattern of inhibition distinct from these two groups. Longitudinal data showed rapid onset and long-lasting duration of the observed effects. Conclusions: Cytochrome P450 3A4 induction by mitotane results in rapid inactivation of more than 50% of administered hydrocortisone, explaining the need for doubling hydrocortisone replacement in mitotane-treated patients. Strong inhibition of 5α-reductase activity is in line with the clinical observation of relative inefficiency of testosterone replacement in mitotane-treated men, calling for replacement by 5α-reduced androgens.

Original languageEnglish
Pages (from-to)161-171
Number of pages11
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number1
DOIs
Publication statusPublished - Jan 2013

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement'. Together they form a unique fingerprint.

Cite this